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Strengths and limitations of this study
 ► This study will involve a qualitative synthesis of 
evidence on antiretroviral treatment (ART) uptake 
and adherence contrary to previous reports that 
have tended to focus on providing quantitative data 
on outcomes of tuberculosis (TB)/HIV integrated 
treatment.
 ► This review will employ a systematic approach in-
volving a critical appraisal of studies such that the 
evidence generated is expected to be of sufficiently 
high quality to adequately inform policy and practice 
in sub-Saharan Africa (SSA).
 ► Independent reviewing and arbitration by a third re-
viewer in case of disagreements will reduce the risk 
of observer bias.
 ► By synthesising evidence on a broad range of driv-
ers of uptake of and adherence to ART, this review 
will highlight important avenues through which HIV 
treatment outcome in the context of integrated TB/
HIV treatment could be optimised in SSA.
 ► This review will not include grey literature and stud-
ies published in languages other than English and 
this will contribute to reporting bias.
AbStrACt
Introduction The scale-up of integrated Human 
Immunodeficiency Virus (HIV) and tuberculosis (TB) 
treatment has been an important intervention to curb 
the burden of HIV and TB co-infection worldwide. Uptake 
of and adherence to antiretroviral therapy (ART) are key 
determinants of the quality and therapeutic endpoints of 
this intervention. This study aims to conduct an up-to-
date collection and synthesis of evidence on barriers to 
and facilitators of uptake of and adherence to ART in HIV/
TB integrated treatment programs in sub-Saharan Africa 
(SSA).
Method A systematic review of peer-reviewed literature 
on the uptake of and adherence to ART in the context 
of integrated therapy for HIV and TB in SSA will be 
performed. We will review qualitative and quantitative 
studies reporting on the uptake of and adherence to 
ART during integrated treatment for TB and HIV among 
adults. These will include studies that involve HIV-infected 
TB patients initiating ART and studies involving PLWHA 
already on ART who are newly diagnosed with TB. 
Qualitative studies, quantitative studies, randomised trials 
and observational studies will be included. Six databases 
including Medline and Embase will be searched for 
relevant studies published from March 2004 to July 2019. 
Two authors will independently screen the search output 
and retrieve full texts of eligible studies. Disagreements 
between the two authors will be resolved by arbitration 
by a third author. Data will be abstracted from the eligible 
studies and synthesis will be done through descriptive 
synthesis for qualitative data and meta-analysis for 
quantitative data.
Ethics and dissemination This study will be a review 
of the literature and will not involve primary collection 
of individuals’ data. Amendments to the protocol will 
be documented in the final review. The final study will 
be published in a peer-reviewed journal and presented 
at conferences. The review is expected to contribute to 
improving strategies to enhance uptake of and adherence 
to ART in integrated care.
PrOSPErO registration number CRD42019131933.
IntrOduCtIOn
Among persons living with HIV/AIDS 
(PLWHA) in low-income settings, tubercu-
losis (TB) remains the principal cause of 
mortality.1–3 In 2017, PLWHA accounted for 
900, 000 (9%) of the estimated 10 million 
new TB disease cases worldwide4 and of the 
900 000 co-infected patients, up to 300 000 
(33.3%) died because of TB.5 The majority 
of these co-infected patients reside in sub-Sa-
haran Africa (SSA); according to the World 
Health Organization (WHO) global TB 
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Table 1 Search strategy for the systematic review
Search # Search words
1 (Antiretroviral therapy OR ART) AND (Uptake OR 
start* OR adher* OR compliance)
2 (Integrat* OR joint OR collaborat* OR concurrent) 
AND (Tuberculosis OR TB) AND (HIV OR AIDS) 
AND (treat* OR therap* OR care OR service)
3 Barrier OR challenge OR drawback OR limitation
4 Enabl* OR facilitat* OR opportunit* OR driver
5 Africa OR Algeria OR Angola OR Benin OR 
Botswana OR Burkina Faso ORBurundi OR 
Cameroon OR Cape Verde OR Central African 
Republic OR Chad ORComoros OR Congo OR 
Democratic Republic of Congo OR Djibouti 
OR Egypt OREquatorial Guinea OR Eritrea OR 
Ethiopia OR Gabon OR Gambia OR Ghana OR 
GuineaOR Guinea Bissau OR Ivory Coast OR 
Cote d’Ivoire OR Jamahiriya OR Jamahiryia 
ORKenya OR Lesotho OR Liberia OR Libya OR 
Libia OR Madagascar OR Malawi OR MaliOR 
Mauritania OR Mauritius OR Mayotte OR 
Morocco OR Mozambique OR Mocambique 
ORNamibia OR Niger OR Nigeria OR Principe OR 
Reunion OR Rwanda OR Sao Tome ORSenegal 
OR Seychelles OR Sierra Leone OR Somalia 
OR South Africa OR St HelenaOR Sudan OR 
Swaziland OR Tanzania OR Togo OR Tunisia 
OR Uganda OR WesternSahara OR Zaire OR 
Zambia OR Zimbabwe OR Central Africa OR 
Central African ORWest Africa OR West African 
OR Western Africa OR Western African OR East 
AfricaOR East African OR Eastern Africa OR 
Eastern African OR North Africa OR NorthAfrican 
OR Northern Africa OR Northern African OR 
South African OR SouthernAfrica OR Southern 
African OR subSaharan Africa OR subSaharan 
African ORsub-Saharan Africa OR sub-Saharan 
African
6 #1 AND #2 AND #3 AND #5
7 #1 AND #2 AND #4 AND #5
ART, antiretroviral therapy; TB, tuberculosis.
report of 2018, up to 72% of all patients co-infected with 
HIV and TB resided in the region.4
From a therapeutic perspective, low-income settings 
of SSA have traditionally relied on separate vertical HIV 
and TB programmes to deliver concurrent HIV and TB 
treatment to co-infected patients.6–11 Based on consider-
able evidence suggesting that better treatment outcomes 
are observed when both programmes are integrated, the 
WHO published policy guidelines regarding the inte-
gration of HIV and TB services.12 Various approaches of 
delivering integrated services have been proposed and 
vary from having the services within one health facility 
to a one-stop-shop strategy in which the services are 
provided as a single package by the same healthcare 
team.13 The first set of guidelines on collaborative HIV/
TB activities (released in 2004) comprised activities 
aimed at integrating TB services into HIV treatment 
settings with the objective of decreasing the burden of 
TB in PLWHA and integrating HIV services into TB 
control programmes with the objective of decreasing the 
burden of HIV in TB patients.12 To reduce the burden 
of TB in PLWHA, WHO recommended intensified TB 
case-finding, isoniazid preventive therapy and infection 
control in healthcare settings. To reduce the burden of 
HIV in TB patients, WHO made an emphasis on HIV 
counselling and testing and HIV prevention methods for 
all TB patients, and cotrimoxazole preventive therapy 
and HIV/AIDS care and support (including antiretro-
viral treatment (ART)) for co-infected patients.12 It is 
worth mentioning that the initial guidelines were based 
on incomplete evidence and were therefore meant to 
serve as provisional guidelines.14
In 2012, the WHO issued a review of the 2004 interim 
guidelines.14 Overall, the updated policy employs the 
same framework as the interim policy but emphasises 
on the establishment of mechanisms for delivering inte-
grated HIV/TB treatment, preferably at the same time 
and location. The mechanisms are expected to be estab-
lished within other programmes such as maternal and 
child health, and prison health services.14 Furthermore, 
monitoring and evaluation of activities linked with inte-
grated HIV/TB treatment are expected to be based on 
standardised indicators and reporting formats. In this 
light, it is worth noting that uptake of and adherence 
to treatment are important indicators of the quality 
and therapeutic outcomes of integrated treatment.14 
The WHO recommends that HIV-infected TB patients 
should be initiated on ART irrespective of their CD4 
count, as timely initiation of ART during TB therapy 
has been shown to significantly improve survival.15 ART 
should be started within 8 weeks of initiation of anti-TB 
treatment and in TB patients with a CD4 count of less 
than 50 cells/mm3, ART should be started within 2 
weeks after the onset of anti-TB treatment.15–17 ART is 
associated with severe adverse events in HIV patients 
with TB meningitis, so ART in these cases should be 
delayed. In the event of TB-associated immune recon-
stitution inflammatory syndrome (IRIS), anti-TB treat-
ment and ART should be continued as IRIS is typically 
self-limiting.18–20
Good coordination and effective communication are 
vital for optimal delivery of the components of inte-
grated treatment but previous reports from SSA generally 
provide quantitative data on coverage and functionality 
of the services, with scarce exploration of qualitative data 
related to ART uptake and adherence which are important 
indicators of the success of integrated treatment. The 
aim of this study is to comprehensively review the litera-
ture and synthesise relevant evidence from which we will 
discuss means of improving ART uptake and adherence 
and HIV treatment outcome during integrated HIV/TB 
treatment in SSA.
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Table 2 Selection criteria for studies to be included in the systematic review
PICOS item Inclusion criteria Exclusion criteria
P-population Studies involving HIV-infected TB patients (adults) 
initiating ART in integrated care OR adults living 
with HIV/AIDS already on ART who are newly 
diagnosed with TB in SSA
Studies involving
 ► Pregnant women and children
 ► Studies conducted out of SSA
I-intervention Studies on uptake of and adherence to ART in the 
setting of integrated therapy for TB and HIV.
 ► Studies describing uptake of and adherence to ART 
in non-integrated treatment settings
 ► Studies on integrated treatment beyond TB and HIV
C-comparison     
O-outcome(s) 1. Barriers to uptake of and adherence to ART
2. Enablers of uptake of and adherence to ART
3. Rates of uptake of and adherence to ART
Studies that do not describe at least one of: barriers, 
enablers or determinants of uptake/adherence.
S-study design Randomised trials, observational studies, 
quantitative studies and qualitative studies 
conducted in hospital and community settings.
1. Mini-reviews, editorials, letters to editors, conference 
abstracts, commentaries, short communications
2. Abstracts whose full data would not be available 
even on requesting from the author
3. Unpublished manuscripts and conference abstracts
4. Duplicate studies: for studies published with the 
same or different titles or in more than one journal, 
the most updated version shall be considered.
ART, antiretroviral therapy; PICOS, population, intervention, comparison, outcome and study; SSA, sub-Saharan Africa; TB, tuberculosis.
research questions
1. What are the barriers to uptake of and adherence to 
ART in integrated treatment for HIV and TB among 
adults in SSA?
2. What are the enablers of uptake of and adherence to 
ART in integrated HIV/TB treatment among adults in 
the region?
research objectives
1. To develop a literature search strategy to identify barri-
ers to and enablers of uptake of and adherence to ART 
in the context of integrated HIV/TB treatment among 
adults in SSA.
2. To screen all the identified studies in (1) for relevance 
to the research questions.
3. To critically appraise the literature obtained from ob-
jective (2).
4. To extract relevant data from studies in (3) on the bar-
riers and enablers of uptake of and adherence to ART 
in integrated HIV/TB treatment among adults in SSA.
5. To conduct a qualitative synthesis and/or a meta-anal-
ysis of the evidence obtained in (4)
6. To draw conclusions on the barriers to and enablers of 
uptake of and adherence to ART in integrated HIV/
TB treatment among adults in SSA.
Methods and analysis
Search strategy
This will be a systematic literature review. Medline, 
Embase, Cochrane, Popline, Scopus and African journal 
online databases will be searched extensively to include 
studies published from 2004 (when the WHO first 
issued recommendations governing integrated HIV/
TB treatment) to July 2019. The search terms and their 
variations that will be used in combination are shown in 
table 1. Articles retrieved from the search will be saved on 
Mendeley desktop software. Two investigators will inde-
pendently screen retrieved titles, abstracts and full texts 
(including those found in reference lists of relevant arti-
cles). In the event of disagreements between the investi-
gators, arbitration will be done by a third investigator.
Selection criteria
The review will include peer-reviewed quantitative and 
qualitative studies on uptake of and adherence to ART 
among patients receiving integrated HIV/TB treatment 
in SSA. The working definition for integrated treatment 
will be the delivery of both antiretroviral and anti-tubercu-
losis drugs to TB/HIV co-infected individuals at the same 
time and location and by the same provider or health-
care team. Table 2 summarises elements of the selection 
criteria based on the population, intervention, compar-
ison, outcome and study design criteria.
The review will include randomised trials and obser-
vational studies published in English. Mixed methods 
studies whose quantitative or qualitative components 
meet the inclusion criteria will be included. Regarding 
qualitative studies, we will include those that specifically 
report on barriers and/or enablers. As concerns quan-
titative studies, those that investigate factors associated 
with uptake and/or adherence of ART (using regression 
models or other methods) in the context of integrated 
treatment for TB and HIV will be included. With regard to 
the study population, we will include studies that involve 
HIV-infected TB patients initiating ART (to identify 
barriers to and enablers of uptake) and studies involving 
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Table 3 CASP checklist for quality assessment of qualitative studies
Criteria Yes No Can’t tell Hint Comments
Section A: are the results of the study valid?
  Was there a clear 
statement of the aims 
of the research?
 ► What was the goal of the research
 ► Why it was thought important
 ► Its relevance
  Is a qualitative 
methodology 
appropriate?
 ► If the research seeks to interpret or illuminate the 
actions and/or subjective experience of research 
participants
 ► is qualitative research the right methodology for 
addressing the research goal
  Is it worth continuing?
  Was the research 
design appropriate to 
address the aims of the 
research?
 ► If the researcher has justified the research design (eg, 
have they discussed how they decided which method 
to use?)
  Was the recruitment 
strategy appropriate 
to the aims of the 
research?
 ► if the researcher has explained how the participants 
were selected
 ► if they explained why the selected participants were 
the most appropriate to provide access to the type of 
knowledge sought by the study
 ► if there are any discussions around recruitment (eg, 
why some people chose not to take part)
  Was the data collected 
in a way that addressed 
the research issue?
 ► if the setting for the data collection was justified
 ► if it is clear how data were collected (eg, focus group, 
semi-structured interview etc.)
 ► if the researcher has justified the methods chosen
 ► if the researcher has made the methods explicit (eg, 
for interview method, is there an indication of how 
interviews are conducted, or did they use a topic 
guide)
 ► if methods were modified during the study. If so, has 
the researcher explained how and why
 ► if the form of data is clear (eg, tape recordings, video 
material, notes etc.)
 ► if the researcher has discussed saturation of data
  Has the relationship 
between researcher 
and participants been 
adequately considered?
 ► if the researcher critically examined their own role, 
potential bias and influence during (a) formulation of 
the research questions (b) data collection, including 
sample recruitment and choice of location
 ► how the researcher responded to events during the 
study and whether they considered the implications of 
any changes in the research design
Section B: what are the results?
  Have ethical issues 
been taken into 
consideration?
 ► if there are sufficient details of how the research was 
explained to participants for the reader to assess 
whether ethical standards were maintained
 ► if the researcher has discussed issues raised by 
the study (eg, issues around informed consent or 
confidentiality or how they have handled the effects 
of the study on the participants during and after the 
study)
 ► if approval has been sought from the ethics 
committee
Continued
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Criteria Yes No Can’t tell Hint Comments
  Was the data analysis 
sufficiently rigorous?
 ► if there is an in-depth description of the analysis 
process
 ► if thematic analysis is used. If so, is it clear how the 
categories/themes were derived from the data
 ► whether the researcher explains how the data 
presented were selected from the original sample to 
demonstrate the analysis process
 ► if sufficient data are presented to support the findings
 ► to what extent contradictory data are taken into 
account
 ► whether the researcher critically examined their own 
role, potential bias and influence during analysis and 
selection of data for presentation
  Is there a clear 
statement of the 
findings?
 ► if the findings are explicit
 ► if there is adequate discussion of the evidence both 
for and against the researcher’s arguments
 ► if the researcher has discussed the credibility of their 
findings (eg, triangulation, respondent validation, 
more than one analyst)
 ► if the findings are discussed in relation to the original 
research question
Section C: will the results help locally?
  How valuable is the 
research?
 ► if the researcher discusses the contribution the study 
makes to existing knowledge or understanding (eg, 
do they consider the findings in relation to current 
practice or policy/or relevant research-based 
literature)
 ► if they identify new areas where research is necessary
 ► if the researchers have discussed whether or how the 
findings can be transformed to other populations or 
considered other ways the research may be used
  Overall risk of bias
  Overall rating/comment
CASP, Critical Appraisal Skills Programme.
Table 3 Continued
PLWHA already on ART who are newly diagnosed with 
TB and commencing anti-tuberculosis drugs (to identify 
barriers to and enablers of adherence) within integrated 
TB/HIV treatment services.
Conference abstracts, editorials, letters to the editor, 
bulletins and grey literature will be excluded. Studies 
with insufficient data on uptake of and adherence to ART 
in the context of collaborative HIV and TB services will 
also be excluded. Online supplementary file 1 shows the 
procedure that will be followed to arrive at the final arti-
cles to be reviewed.
data extraction and synthesis
Two investigators will extract the relevant data from each 
article included. A data extraction form and definitions of 
key terms will be developed to standardise the data collec-
tion process. The extracted data will be saved on a Micro-
soft Excel 2016 form and subsequently double-checked 
for accuracy by a third investigator. We will include data 
on
1. Publication details: first author name, publication year, 
journal reference, country and place of study, year of 
study, study design, study area and setting, study popu-
lation, sample size, characteristics of patients (such as 
age and sex distribution, WHO stage), as well as limita-
tions and strengths of studies.
2. Primary outcomes:
a. Barriers to uptake of and adherence to ART in inte-
grated care.
b. Facilitators of uptake of and adherence to ART in 
integrated care.
c. For qualitative studies, specific barriers and enablers 
will be extracted as reported in the studies. With 
regard to quantitative studies investigating factors 
associated with uptake and/or adherence of ART, 
factors that are associated with poor uptake or ad-
herence will be considered as barriers while factors 
that are associated with good uptake or adherence 
will be considered as facilitators.
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3. Secondary outcomes: ART uptake (measured as the 
proportion of those diagnosed who initiated ART) 
and adherence (estimated as the ratio of the num-
ber of ART doses taken to the number of doses pre-
scribed over a given time period measured through 
pill count, directly observed therapy, electronic data 
records and other self-reported and objective mea-
sures) . These outcomes will be reported as the over-
all mean ART uptake and the overall mean adherence 
rate reported in eligible studies. These overall means 
will be derived from meta-analysis on Statistics and 
Data (STATA) software version 15 to pool the report-
ed estimates on uptake and adherence obtained from 
eligible studies with the relevant data. The conduct 
of meta-analysis will depend on whether studies with 
uptake and adherence rates are generally homoge-
nous in terms of the intervention (integrated treat-
ment), study design, study populations and measures 
of the outcomes. Because the eligibility criteria for 
ART initiation are expected to vary with time and 
setting (during the period under review), we will as-
certain that uptake is in accordance with contempo-
rary WHO guidelines in order to avoid heterogeneity 
in the reporting of uptake (a secondary outcome). 
When methodological aspects of a study could affect 
the observed outcome (uptake/adherence) in spe-
cific studies, sensitivity analysis that will consist in re-
stricting the meta-analysis to the other studies will be 
performed. Pooled estimates will be reported on for-
est plots while risk of publication bias will be assessed 
by means of funnel plots. Sub-group analyses will be 
performed where appropriate.
A thematic synthesis approach will be used to analyse 
and synthesise the extracted data on barriers and enablers. 
Two investigators will develop the initial coding frame-
work on Microsoft Excel 2016 by reading through eligible 
studies to identify the main themes. These themes will be 
developed from the earlier listed outcomes of interest. 
The coding framework will be progressively amended to 
incorporate more themes and sub-themes that emerge as 
each eligible study is reviewed.
The quality of qualitative studies will be graded using the 
Critical Appraisal Skills Programme checklist (table 3)21 
while that of interventional and observational studies will 
be assessed using their respective quality assessment tools 
as per the National Health Institute (National Heart, 
Lung, and Blood Institute).22 For mixed-methods studies, 
the quality of the qualitative and quantitative components 
will be assessed using the appropriate tool as described 
earlier. Overall study quality will be rated as good, fair or 
poor. For quantitative evidence, the confidence in the 
synthesised evidence will be rated using the Grading of 
Recommendations, Assessment, Development and Eval-
uation approach. For qualitative evidence, the confi-
dence in the synthesised evidence will be rated using the 
Grading of Recommendations, Assessment, Development 
and Evaluation-Confidence in the Evidence from Reviews 
of Qualitative Studies.
The final review will be reported as per the guidelines 
of the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis guidelines (online supplementary file 
2). Important amendments will be documented in the 
final review.
Patient and public involvement
There was no patient or public involvement in the design 
or planning of the study.
COnCluSIOn
This systematic review will explore factors that enable and 
obstruct uptake of and adherence to ART when HIV/
TB treatment services are integrated in SSA settings. The 
conduct of the review will be in four parts: identification 
of relevant studies, study inclusion, data extraction and 
data synthesis. The results of this review will benefit co-in-
fected patients, clinicians and policy makers. The main 
limitation of the review is that it will not include studies 
that are not published in English as well as non-ran-
domised trials and this could reduce the range of barriers 
and facilitators identified. Nonetheless, the study is one 
of the rare attempts to fill in the alarming lack of data on 
the subject matter and the quality of included reports and 
the confidence in the evidence will be ascertained using 
standard tools, which will enable the generation of valid 
conclusions in the final report.
EthICS And dISSEMInAtIOn
This study will be a systematic review of the literature 
and will not involve primary collection of individuals 
data. Amendments to the protocol will be documented 
in the final review. The final study will be published in a 
peer-reviewed journal and presented at conferences. The 
review is expected to contribute to the knowledge base 
of barriers to and enablers of uptake of and adherence 
to ART during integrated treatment for TB/HIV. Filling 
this knowledge gap is expected to go a long way to inform 
policy and practice and improve integrated TB/HIV 
treatment outcomes in SSA.
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